1-9 of 9
Christopher W. Ryan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers

Young Kwang Chae, Lucy Corthell, Sandip Pravin Patel, Robert Edwards, Jennifer M. Scalici, Hye Sung Kim, Liam Il-Young Chung, Megan Othus, Christine M. McLeod, Helen X. Chen, Elad Sharon, Howard Streicher, Christopher W. Ryan, Charles D. Blanke, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (2): 308–315.
https://doi.org/10.1158/1078-0432.CCR-24-1957
Published: 17 January 2025
View article titled, A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers
Open the PDF for A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers in another window
Includes: Supplementary data
Journal Articles

SWOG/NCI Phase II Dual Anti–CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer

Young Kwang Chae, Megan Othus, Sandip Pravin Patel, Kelly J. Wilkinson, Emily M. Whitman-Purves, Jayanthi Lea, John M. Schallenkamp, Nabil Adra, Leonard J. Appleman, Mitchell Alden, Jessica Thomes Pepin, John A. Ellerton, Andrew Poklepovic, Adam Walter, Murtuza M. Rampurwala, William R. Robinson, Hye Sung Kim, Liam Il-Young Chung, Christine M. McLeod, Gabby Lopez, Helen X. Chen, Elad Sharon, Howard Streicher, Christopher W. Ryan, Charles D. Blanke, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (24): 5593–5600.
https://doi.org/10.1158/1078-0432.CCR-24-0606
Published: 16 December 2024
View article titled, SWOG/NCI Phase II Dual Anti–CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer
Open the PDF for SWOG/NCI Phase II Dual Anti–CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non–Clear Cell Renal Cell Carcinoma

Andrew J. Armstrong, Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, Jorge A. Garcia, Ulka N. Vaishampayan, Joel Picus, Robert E. Hawkins, John D. Hainsworth, Christian K. Kollmannsberger, Theodore F. Logan, Igor Puzanov, Lisa M. Pickering, Christopher W. Ryan, Andrew Protheroe, Daniel J. George, Susan Halabi
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (12): 3503.
https://doi.org/10.1158/1078-0432.CCR-21-1636
Published: 15 June 2021
View article titled, Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non–Clear Cell Renal Cell Carcinoma
Open the PDF for Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non–Clear Cell Renal Cell Carcinoma in another window
Journal Articles

Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma

Andrew J. Armstrong, Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, Jorge A. Garcia, Ulka N. Vaishampayan, Joel Picus, Robert E. Hawkins, John D. Hainsworth, Christian K. Kollmannsberger, Theodore F. Logan, Igor Puzanov, Lisa M. Pickering, Christopher W. Ryan, Andrew Protheroe, Daniel J. George, Susan Halabi
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (12): 3317–3328.
https://doi.org/10.1158/1078-0432.CCR-20-4504
Published: 15 June 2021
View article titled, Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma
Open the PDF for Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

Sandip P. Patel, Megan Othus, Young Kwang Chae, Francis J. Giles, Donna E. Hansel, Preet Paul Singh, Annette Fontaine, Manisha H. Shah, Anup Kasi, Tareq Al Baghdadi, Marc Matrana, Zoran Gatalica, W. Michael Korn, Jourdain Hayward, Christine McLeod, Helen X. Chen, Elad Sharon, Edward Mayerson, Christopher W. Ryan, Melissa Plets, Charles D. Blanke, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (10): 2290–2296.
https://doi.org/10.1158/1078-0432.CCR-19-3356
Published: 15 May 2020
View article titled, A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors
Open the PDF for A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of Preoperative Chemoradiation plus Sorafenib for High-Risk Extremity Soft Tissue Sarcomas with Dynamic Contrast-Enhanced MRI Correlates

Janelle M. Meyer, Kelly S. Perlewitz, James B. Hayden, Yee-Cheen Doung, Arthur Y. Hung, John T. Vetto, Rodney F. Pommier, Atiya Mansoor, Brooke R. Beckett, Alina Tudorica, Motomi Mori, Megan L. Holtorf, Aneela Afzal, William J. Woodward, Eve T. Rodler, Robin L. Jones, Wei Huang, Christopher W. Ryan
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (24): 6902–6911.
https://doi.org/10.1158/1078-0432.CCR-13-1594
Published: 16 December 2013
View article titled, Phase I Trial of Preoperative Chemoradiation plus Sorafenib for High-Risk Extremity Soft Tissue Sarcomas with Dynamic Contrast-Enhanced MRI Correlates
Open the PDF for Phase I Trial of Preoperative Chemoradiation plus Sorafenib for High-Risk Extremity Soft Tissue Sarcomas with Dynamic Contrast-Enhanced MRI Correlates in another window
Journal Articles

Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer

Mary-Ellen Taplin, Meredith M. Regan, Yoo-Joung Ko, Glenn J. Bubley, Stephen E. Duggan, Lillian Werner, Tomasz M. Beer, Christopher W. Ryan, Paul Mathew, Shi-Ming Tu, Samuel R. Denmeade, William K. Oh, Oliver Sartor, Christos S. Mantzoros, Roger Rittmaster, Philip W. Kantoff, Steven P. Balk
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (22): 7099–7105.
https://doi.org/10.1158/1078-0432.CCR-09-1722
Published: 11 November 2009
View article titled, Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer
Open the PDF for Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer in another window
Journal Articles

Dose-Ranging Study of the Safety and Pharmacokinetics of Atrasentan in Patients with Refractory Malignancies

Christopher W. Ryan, Nicholas J. Vogelzang, Everett E. Vokes, Hedy L. Kindler, Samir D. Undevia, Rod Humerickhouse, Amy K. André, Qiang Wang, Robert A. Carr, Mark J. Ratain
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (13): 4406–4411.
https://doi.org/10.1158/1078-0432.CCR-04-0083
Published: 06 July 2004
View article titled, Dose-Ranging Study of the Safety and Pharmacokinetics of Atrasentan in Patients with Refractory Malignancies
Open the PDF for Dose-Ranging Study of the Safety and Pharmacokinetics of Atrasentan in Patients with Refractory Malignancies in another window
Journal Articles

A Randomized Phase II Trial of the Antiangiogenic Agent SU5416 in Hormone-Refractory Prostate Cancer

Walter M. Stadler, Dingcai Cao, Nicholas J. Vogelzang, Christopher W. Ryan, Kristin Hoving, Russell Wright, Theodore Karrison, Everett E. Vokes
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (10): 3365–3370.
https://doi.org/10.1158/1078-0432.CCR-03-0404
Published: 24 May 2004
View article titled, A Randomized Phase II Trial of the Antiangiogenic Agent SU5416 in Hormone-Refractory Prostate Cancer
Open the PDF for A Randomized Phase II Trial of the Antiangiogenic Agent SU5416 in Hormone-Refractory Prostate Cancer in another window